GENetic characteristics and REsponse to lipid-lowering therapy in familial hypercholesterolemia: GENRE-FH study (Q101476186)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

title

GENetic characteristics and REsponse to lipid-lowering therapy in familial hypercholesterolemia: GENRE-FH study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

familial hypercholesterolemia

11 November 2020

main subject

1 reference

Hyoeun Kim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Chan Joo Lee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Hayeon Pak

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Doo-Il Kim

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Moo-Yong Rhee

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Byoung Kwon Lee

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Youngkeun Ahn

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Byung-Ryul Cho

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Jeong-Taek Woo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Seung-Ho Hur

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Jin-Ok Jeong

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Ji Hyun Lee

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

Sang-Hak Lee

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

publication date

9 November 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

11 November 2020

page(s)

19336

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168860 AND SRC:MED&resulttype=core&format=json

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

11 November 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia - A study supported by Korean Society of Lipidology and Atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Genetic testing of Korean familial hypercholesterolemia using whole-exome sequencing

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe).

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Interpretation of the evidence for the efficacy and safety of statin therapy

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-R

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Large-scale genome-wide association studies in East Asians identify new genetic loci influencing metabolic traits

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Cardiovascular risk stratification in familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH).

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH)

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R).

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Functional characterization and classification of frequent low-density lipoprotein receptor variants.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038/S41598-020-75901-0

7 January 2021